HER-2 gene amplification can be acquired as breast cancer progresses.
暂无分享,去创建一个
Tanja Fehm | Sanjay Shete | Leon W M M Terstappen | Nancy Lane | David Euhus | Susan Hoover | Raheela Ashfaq | T. Fehm | S. Shete | D. Tripathy | E. Frenkel | R. Ashfaq | L. Morrison | J. Uhr | N. Lane | T. Fleming | L. Terstappen | D. Euhus | B. Haley | P. Beitsch | S. Hoover | E. Vitetta | M. Leitch | Dorothee Herlyn | Edward Clifford | Peter Beitsch | Songdong Meng | Larry Morrison | Thomas Tucker | Jonathan Uhr | Eugene Frenkel | Debasish Tripathy | Cynthia Osborne | E. Clifford | D. Herlyn | T. Tucker | Barbara Haley | S. Meng | Jianqiang Wang | Steve Perkins | Amanullah Khan | Marilyn Leitch | Ellen Vitetta | Timothy Fleming | Jianqiang Wang | C. Osborne | Amanullah Khan | S. Perkins
[1] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[2] G. Gray,et al. Targeted therapy for cancer: the HER-2/neu and Herceptin story. , 2003, Clinical leadership & management review : the journal of CLMA.
[3] J. Nesland,et al. Detection of c-erbB-2 related protein in sera from breast cancer patients. Relationship to ERBB2 gene amplification and c-erbB-2 protein overexpression in tumour. , 1995, Acta oncologica.
[4] R. Molina,et al. C-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer. Utility in prognosis. , 1996, Anticancer research.
[5] Tanja Fehm,et al. Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[6] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[7] J. Uhr,et al. Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. , 2002, International journal of oncology.
[8] L. Seymour,et al. Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer. , 1994, British journal of cancer.
[9] J. Isola,et al. Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. , 2001, Cancer research.
[10] A. Jackson,et al. The mutation rate and cancer. , 1998, Genetics.
[11] M. Herlyn,et al. Efficient selection of human tumor growth-inhibiting monoclonal antibodies. , 1984, Journal of immunological methods.
[12] P. Möller,et al. Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. , 1987, Cancer research.
[13] Meenakshi Singh,et al. Her-2/neu status in breast cancer metastases to the central nervous system. , 2009, Archives of pathology & laboratory medicine.
[14] N. Personeni,et al. HER‐2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma , 2003, Cancer.
[15] C. Shimizu,et al. c‐erbB‐2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues , 2000, Journal of surgical oncology.
[16] C. Rao,et al. Optimization of ferrofluids and protocols for the enrichment of breast tumor cells in blood , 2001 .
[17] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[18] A. Weiss,et al. Detection and characterization of carcinoma cells in the blood. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[19] D. Larsimont,et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] S. Takekoshi,et al. Heterogeneous gene alterations in primary breast cancer contribute to discordance between primary and asynchronous metastatic/recurrent sites: HER2 gene amplification and p53 mutation. , 2003, International journal of oncology.